Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol
February 11 2021 - 8:00AM
InvestorsHub NewsWire
VANCOUVER, British Columbia, Feb. 10, 2021 --
InvestorsHub NewsWire -- Algernon Pharmaceuticals
Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical
stage pharmaceutical development company is pleased to announce
that it has decided to review its protocol for its phase 2b/3 study
of Ifenprodil for COVID-19, to consider adding lung scarring as an
additional endpoint if sufficient data is available from a
significant number of patients.
When Algernon wrote its original phase 2b/3
protocol last April 2020, lung scarring, post hospital release, had
not yet been established as a major problem with recovering
COVID-19 patients, so it was not included.
Each hospital that participated in the COVID-19
study was left to manage their site-specific standard of care
protocol for releasing a patient. While most hospitals will X-ray
on admission of a COVID-19 patient, only some hospitals will X-ray
before discharging a patient because they will use other clinical
markers.
"If we determine that X-rays were taken on
release of a meaningful number of our treated patients, and
Ifenprodil is showing a reduction in the amount of scarring post
infection, this would be an extremely important discovery for us,"
said Christopher J. Moreau, CEO of Algernon. "If this is confirmed
in the planned Phase 3 portion of the study, it would mean that
Ifenprodil could be used to treat patients who have survived
COVID-19 but are suffering from lung damage."
In a recent Oxford University Study, researchers
found 60 per cent of patients had scarring or inflammation in their
lungs three months after clearing the virus.
The Company advises that it is not making any
express or implied claims that Ifenprodil has the ability to
eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at
this time.
About Algernon Pharmaceuticals
Inc.
Algernon is a drug re-purposing company that
investigates safe, already approved drugs, including naturally
occurring compounds, for new disease applications, moving them
efficiently and safely into new human trials, developing new
formulations and seeking new regulatory approvals in global
markets. Algernon specifically investigates compounds that have
never been approved in the U.S. or Europe to avoid off label
prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Neither the Canadian Securities
Exchange nor its Market Regulator (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
CAUTIONARY DISCLAIMER STATEMENT: No
Securities Exchange has reviewed nor accepts responsibility for the
adequacy or accuracy of the content of this news release. This news
release contains forward-looking statements relating to product
development, licensing, commercialization and regulatory compliance
issues and other statements that are not historical facts.
Forward-looking statements are often identified by terms such as
"will", "may", "should", "anticipate", "expects" and similar
expressions. All statements other than statements of historical
fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and
future events could differ materially from those anticipated in
such statements. Important factors that could cause actual results
to differ materially from the Company's expectations include the
failure to satisfy the conditions of the relevant securities
exchange(s) and other risks detailed from time to time in the
filings made by the Company with securities regulations. The reader
is cautioned that assumptions used in the preparation of any
forward-looking information may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements as expressly required by
applicable law.
Algernon Pharmaceuticals (CSE:AGN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Algernon Pharmaceuticals (CSE:AGN)
Historical Stock Chart
From Dec 2023 to Dec 2024